Compugen Revolutionizes Cancer Research with Enhanced AI/ML Platform and Single Cell Sequencing Technology

Compugen Enhances AI/ML Capabilities with Ultima Genomics Technology

Compugen Ltd., a trailblazer in the field of cancer immunotherapy and predictive computational discovery, recently announced a significant advancement in its research capabilities. By integrating its powerful AI/ML predictive computational discovery platform, Unigen™, with Ultima Genomics' UG 100™ single cell sequencing technology, the company aims to enhance the understanding of gene structure in tumor biology and immune regulation.

The collaboration, showcased at the Advances in Genome Biology and Technology (AGBT) 2025 General Meeting, promises to push the boundaries of current immuno-oncology research. Compugen's Chief Scientific Officer, Dr. Eran Ophir, expressed excitement about this collaboration, which aims to enhance their proprietary gene sequencing database. The combination of advanced algorithms and high-throughput sequencing is expected to reveal new insights into gene splicing at a single-cell level, thereby uncovering potential regulatory mechanisms that could lead to more effective immunotherapies.

Research Findings and Implications

In a comparative analysis involving tumor samples from several cancer patients, researchers found striking consistency in single-cell expression levels across the UG 100 platform and another leading technology, Illumina's Novaseq 6000. This consistency is significant as it allows for clearer identification of the mRNA transcript's 3' end, which can greatly facilitate the study of gene structures relevant for understanding both tumor biology and immune responses.

According to Dr. Roy Granit, who leads the Computational Discovery at Compugen and presented the findings, the insights gleaned from this research could significantly strengthen the predictive models within the Unigen platform. This advancement positions Compugen at the forefront of immunotherapy development, potentially accelerating the discovery of new targets for cancer treatment.

The Future of Immuno-Oncology

The implications of leveraging Ultima's sequencing technology extend beyond mere data acquisition. Gilad Almogy, the Founder and CEO of Ultima Genomics, underscored the potential of this partnership. He noted that conventional sequencing technologies often limit data availability for many research applications, a gap that their UG 100 platform is designed to fill. The innovation brought forth by this technology is an excellent example of merging extensive data with advanced AI and machine learning techniques to revolutionize research capabilities in the oncology field.

Moving forward, Compugen aims to harness Ultima's pioneering technology to develop proprietary single-cell atlases. This initiative is expected to facilitate a faster and more effective discovery of new immunotherapies which could redefine treatment options for cancer patients.

About Unigen™ and Compugen

Compugen's Unigen™ platform has become synonymous with innovation in cancer research. This code-to-cure approach is built to flexibly predict drug targets and develop immunotherapeutic solutions tailored to modern clinical challenges. The technology integrates a variety of biological data from multiple sources, including spatial omics data and single-cell RNA sequencing. Such integrations fuel an expanding knowledge base that informs further drug target discovery, thereby enhancing overall cancer treatment efficacy.

With promising candidates already entering clinical trials, including innovative antibodies targeting essential pathways in tumor immunity, Compugen is firmly positioned to contribute meaningful advancements to the field. The company's pipeline consists of several exciting programs aimed at overcoming immune resistance mechanisms, showcasing their commitment to leading the way in cancer therapeutics.

Compugen, headquartered in Israel with additional offices in San Francisco, CA, holds its shares listed on both the Nasdaq and Tel Aviv stock exchanges under the ticker CGEN. As clinical-stage developments evolve, Compugen continues to pave the path toward new horizons in the fight against cancer through state-of-the-art technology and collaborative innovation.

For more details on the research discussed, visit Compugen's website at www.cgen.com for access to the poster presentation and comprehensive information about the Unigen™ platform and ongoing projects.